Document is current
Any future updates will be listed below
-
Authors
Tomasello, Laura https://orcid.org/0000-0002-2304-6007
Guarnotta, Valentina https://orcid.org/0000-0002-8088-4947
Siragusa, Giuseppe https://orcid.org/0009-0007-4734-0773
Biondo, Mattia https://orcid.org/0009-0002-6880-2192
Arnaldi, Giorgio https://orcid.org/0000-0002-6204-3423
Giordano, Carla https://orcid.org/0000-0003-1731-9395
Pizzolanti, Giuseppe https://orcid.org/0000-0001-6052-8438
-
Funding
Funding for this research was provided by:
PNRR M4C2I1.3 Samothrace (PRJ-1103)
- License Information
-
More Information
Article History
Received: 3 April 2025
Revised: 3 December 2025
Accepted: 5 December 2025
First Online: 15 December 2025
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee Palermo, AOUP Paolo Giaccone, protocol n.420/18, code 08/2018, date of approval 10.09.2018. Written informed consent was obtained from all participants.
: Written informed consent for publication of their clinical details was obtained from the patient.
: The authors declare that they have applied for two patents concerning the possible use of fibroblast‐like limbal stem cells in type 1 diabetes (PCT/EP2010/070860) and autoimmunity diseases (PCT/EP2017/082380). We declare that none of the co‐authors have any non‐financial competing interests in relation to this manuscript.
